Items where Author is "Huber, C."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 2.

Article

Lordick, F. and Schuler, M. and Al-Batran, S-E. and Zvirbule, Z. and Manikhas, G. and Rusyn, A. and Vinnyk, Y. and Vynnychenko, I. and Fadeeva, N. and Nechaeva, M. and Dudov, A. and Gotovkin, E. and Pecheniy, A. and Bazin, I. and Bondarenko, I. and Melichar, B. and Huber, C. and Sahin, U. and Türeci, Ö. (2016) Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology, 27 (supp_9). mdw582.001. ISSN 0923-7534 (Print), 1569-8041 (Electronic)

Schuler, M. and Al-Batran, S.-E. and Zvirbule, Z. and Manikhas, G. and Lordick, F. and Rusyn, A. and Vinnyk, Y. and Vynnychenko, I. and Fadeeva, N. and Nechaeva, M. and Dudov, A. and Gotovkin, E. and Pecheniy, A. and Bazin, I. and Bondarenko, I. and Melichar, B. and Huber, C. and Türeci, Ö. and Sahin, U. (2016) Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology, Vol.27 (supp_6). P.- LBA45. ISSN 0923-7534 (Print), 1569-8041 (Electronic)

This list was generated on Thu Mar 28 02:11:46 2024 EET.